drugset / Trial / NCT00875524
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
RandomizedParallel-groupTriple-blindPrevention
Summary
This trial evaluated the use of a tetravalent vaccine against dengue. Primary objectives: * To describe the humoral immune response to dengue before and after each vaccination with tetravalent dengue vaccine in adults, adolescents, and children. * To evaluate the safety of each vaccination with tetravalent dengue vaccine in the 4 age cohorts. * To evaluate the persistence of antibodies against dengue during 5 years after the first vaccination with tetravalent dengue vaccine in the 4 age cohorts.
Timeline
- Start
- 2009-03
- Primary completion
- 2014-08
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CYD Dengue Vaccine | Vaccine | 0.5 ml | Subcutaneous |
| Comparator | Meningococcal Polysaccharide A+C | Vaccine | 0.5 ml | Subcutaneous |
| Comparator | Typhim Vi | Vaccine | 0.5 ml | Subcutaneous |